| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5506725 | Biochemical and Biophysical Research Communications | 2016 | 6 Pages |
Abstract
This study is the first to indicate that low doses of atorvastatin and rosuvastatin, the dosing regimen for which has been controversial, could significantly improve diabetes-related metabolic disorders, and could modulate pro-inflammatory cytokines, alleviating inflammation and simultaneously restoring overall humoral and cell-mediated immunity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Sungwon Lee, Youngjoo Lee, Jiyeon Kim, Jinho An, Kwanghee Kim, Heetae Lee, Hyunseok Kong, Youngcheon Song, Kyungjae Kim,